Apogee Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis. Apogee is advancing a pipeline of additional RORγt-focused programs with potential applications across dermatology and immunology, including conditions such as alopecia areata and lichen planus. Preclinical studies have demonstrated target engagement and a favorable safety profile, supporting the company’s approach to address high-unmet needs in T cell-mediated disease.
Headquartered in the United States, Apogee has established research and development operations to support medicinal chemistry, translational biology and clinical trial execution. The company collaborates with academic centers and contract research organizations to conduct multi-center studies in North America and Europe, generating data to inform regulatory strategy and future growth.
Apogee’s management team brings together experienced leaders in immunology, drug discovery and clinical development. Drawing on a track record of advancing small molecule candidates through regulatory review, the leadership group is focused on driving its RORγt platform toward clinical proof-of-concept and preparing for potential partnerships or collaborations to expand the company’s reach in inflammatory and autoimmune therapeutics.
AI Generated. May Contain Errors.
Free APGE Stock Alerts